Regeneron Pharmaceuticals Inc. buy Citigroup Inc.
Summary
This prediction ended on 03.06.26 with a price of €513.10. The prediction had a final performance of 19.83%. Citigroup_Inc_ has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Dividends of €3.64 are taken into consideration when calculating the performance. Citigroup_Inc_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.600% | -0.600% | 40.335% |
| iShares Core DAX® | -0.046% | 5.960% | 7.403% |
| iShares Nasdaq 100 | 0.922% | 3.693% | 28.138% |
| iShares Nikkei 225® | 3.014% | 6.638% | 48.886% |
| iShares S&P 500 | -0.359% | 2.747% | 22.530% |
Comments by Citigroup_Inc_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
13.10.25
13.10.26
19:41
Stopped prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
29.10.25
29.10.26
19:41
Regeneron Pharmaceuticals Inc.
14.05.25
14.05.26
15.05.26

